Patents Represented by Attorney, Agent or Law Firm David J. Earp
-
Patent number: 7824849Abstract: The invention provides dendritic cell (DC) preparations that present a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DCs may be pulsed with a TRT polypeptide, or may comprise a recombinant polynucleotide encoding TRT. The invention also describes the use of such compositions for the prevention and treatment of cancers and other diseases.Type: GrantFiled: April 27, 2006Date of Patent: November 2, 2010Assignee: Geron CorporationInventor: Federico C. A. Gaeta
-
Patent number: 7732402Abstract: Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.Type: GrantFiled: February 7, 2003Date of Patent: June 8, 2010Assignee: Geron CorporationInventors: Bryant Villeponteau, Junli Feng, Walter Funk, William Andrews
-
Patent number: 7256042Abstract: It has been discovered that when pluripotent stem cells are cultured in the presence of a hepatocyte differentiation agent, a population of cells is derived that has a remarkably high proportion of cells with phenotypic characteristics of liver cells. In one example, human embryonic stem cells are allowed to form embryoid bodies, and then combined with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. Either way, a remarkably uniform cell population is obtained, which is predominated by cells with morphological features of hepatocytes, expressing surface markers characteristic of hepatocytes, and having enzymatic and biosynthetic activity important for liver function.Type: GrantFiled: October 31, 2001Date of Patent: August 14, 2007Assignee: Geron CorporationInventors: Lakshmi Rambhatla, Melissa K. Carpenter
-
Patent number: 7199234Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: December 20, 2002Date of Patent: April 3, 2007Assignee: Geron CorporationInventors: Gregg B. Morin, William H. Andrews
-
Patent number: 7138383Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3?-NHP(O)(S?)O-5? linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3??P5? phosphoramidates and to exhibit a much higher acid stability.Type: GrantFiled: October 18, 2004Date of Patent: November 21, 2006Assignee: Geron CorporationInventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
-
Patent number: 6833269Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: May 31, 2001Date of Patent: December 21, 2004Assignee: Geron CorporationInventor: Melissa K. Carpenter
-
Patent number: 6808880Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.Type: GrantFiled: January 19, 2001Date of Patent: October 26, 2004Assignees: Geron Corporation, Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin Harley, William H. Andrews
-
Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
Patent number: 6800480Abstract: Methods and materials for culturing primate-derived primordial stem cells are described. In one embodiment, a cell culture medium for growing primate-derived primordial stem cells in a substantially undifferentiated state is provided which includes a low osmotic pressure, low endotoxin basic medium that is effective to support the growth of primate-derived primordial stem cells. The basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate selected from the group consisting of feeder cells and an extracellular matrix component derived from feeder cells. The medium further includes non-essential amino acids, an anti-oxidant, and a first growth factor selected from the group consisting of nucleosides and a pyruvate salt.Type: GrantFiled: August 29, 2000Date of Patent: October 5, 2004Assignee: Geron CorporationInventors: Andrea G. Bodnar, Choy-Pik Chiu, Joseph D. Gold, Margaret Inokuma, James T. Murai, Michael D. West -
Patent number: 6787133Abstract: This invention provides purified telomerase and methods of purifying it. The methods involve the use of several sequential steps, including the use of matrices that bind molecules bearing negative charges, matrices that bind molecules bearing positive charges, intermediate-selectivity matrices, methods that separate molecules based on their size, shape, or buoyant density, and by affinity purification.Type: GrantFiled: December 24, 2002Date of Patent: September 7, 2004Assignee: Geron CorporationInventors: Scott L. Weinrich, Edward M. Atkinson, III, Serge P. Lichtsteiner, Alain P. Vasserot, Ronald A. Pruzan
-
Patent number: 6777203Abstract: The present invention is related to novel nucleic acids comprising telomerase reverse transcriptase (TERT) cis-acting transcriptional control sequences, including TERT human and mouse promoter sequences. The present invention is further directed to methods of using these cis-acting transcriptional control sequences, for example, to drive heterologous gene sequences; to modulate the level of transcription of TERT or to isolate novel trans-acting regulatory factors which bind to and modulate the activity of a TERT promoter.Type: GrantFiled: February 4, 1999Date of Patent: August 17, 2004Assignee: Geron CorporationInventors: Gregg B. Morin, Serge P. Lichtsteiner, Alain P. Vasserot, Robert R. Adams, William H. Andrews
-
Patent number: 6767719Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.Type: GrantFiled: March 16, 1998Date of Patent: July 27, 2004Assignees: Geron Corporation, Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventors: Gregg B. Morin, Richard Allsopp, Ronald A. DePinho, Roger A. Greenberg
-
Patent number: 6713055Abstract: This disclosure provides a system for specifically killing cancer cells which can be used in the course of human therapy. Vectors of the invention comprise an encoding sequence for a glycosyltransferase, under control of a tumor or tissue specific transcriptional control element, such as the promoter for telomerase reverse transcriptase. Exemplary glycosyltransferases are the A or B transferase enzymes, which cause the cancer cells to express ABO histo blood group allotypes against which humans have naturally occurring antibody. This provides for ongoing surveillance for newly emerging cells with a malignant phenotype.Type: GrantFiled: November 26, 2001Date of Patent: March 30, 2004Assignee: Geron CorporationInventor: J. Michael Schiff
-
Patent number: 6673987Abstract: Pregnancy in animals such as the pig usually does not continue to term when there are only a few embryos in the uterus. Currently available technology for maintaining pregnancy involves a series of hormone injections, and the failure rate is high. It has now been discovered that pregnancy can be maintained by complementing fertile embryos in the uterus with additional embryos that aren't expected to survive the full term of the pregnancy. Particularly suitable are parthenogenetic embryos, formed by activating and diploidizing unfertilized oocytes. The carrier embryos are engrafted into the uterus of a surrogate female, and the pregnancy continues to term without further intervention—even if the number of fertile embryos are below the minimum litter size. This provides valuable biological material that can be used for transplantation, the production of pharmaceuticals, and for agricultural use.Type: GrantFiled: March 29, 2000Date of Patent: January 6, 2004Assignee: Geron CorporationInventor: Timothy J. King
-
Patent number: 6667176Abstract: This disclosure provides a system for obtaining expression libraries from primate pluripotent stem (pPS) cells. pPS cells can be maintained in vitro without requiring a layer of feeder cells to inhibit differentiation. The role of the feeder cells is replaced by several other culture conditions provided in a suitable combination. Conditions that promote pPS cell growth without differentiation include supporting the culture on an extracellular matrix, and culturing the cells in a medium conditioned by another cell type. The cDNA libraries from such cultures are devoid of transcripts of feeder cell origin, relatively uncontaminated by transcripts from differentiated cells, and can have a high proportion of full-length transcripts. Subtraction libraries can also be produced that are enriched for transcripts modulated during differentiation.Type: GrantFiled: October 10, 2000Date of Patent: December 23, 2003Assignee: Geron CorporationInventors: Walter D. Funk, Melissa K. Carpenter, Joseph D. Gold, Margaret S. Inokuma, Chunhui Xu
-
Patent number: 6642048Abstract: This invention provides media that support the growth of primate pluripotent stem cells in feeder-free culture, and cell lines useful for producing such media and other purposes. Conventionally, it has been necessary to grow pluripotent embryonic cells on feeder layers of primary embryonic fibroblasts, in order to prevent them from differentiating. It has now been discovered that standard culture media conditioned by special cell lines can be used to support proliferation of pluripotent stem cells while inhibiting differentiation in an environment free of feeder cells. This invention includes mesenchymal and fibroblast-like cell lines obtained from embryonic tissue or differentiated from embryonic stem cells. Methods for deriving such cell lines, processing media, and growing stem cells using the conditioned media are described and illustrated in this disclosure.Type: GrantFiled: July 6, 2001Date of Patent: November 4, 2003Assignee: Geron CorporationInventors: Chunhui Xu, Joseph D. Gold
-
Patent number: 6627619Abstract: The present invention provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.Type: GrantFiled: September 14, 2001Date of Patent: September 30, 2003Assignees: Geron Corporation, University Technology CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6617110Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: November 24, 2000Date of Patent: September 9, 2003Assignees: Geron Corporation, University Technology CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6610839Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of humana diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: September 29, 1999Date of Patent: August 26, 2003Assignee: Geron CorporationInventors: Gregg B. Morin, William H. Andrews
-
Patent number: 6599728Abstract: A new protein named Tankyrase II is described in this disclosure. Sequences for the human Tankyrase II cDNA and the protein translation product are provided. Also provided are species homologs, muteins, related nucleic acids, peptides, and drug screening assays. Tankyrase II interacts with telomere-associated proteins, thereby affecting telomerase activity and potentially telomere length. The materials and techniques provided in this disclosure allow Tankyrase II activity to be studied in vitro and manipulated inside cells—to the potential benefit of clinical conditions associated with a defect in telomerase activity, or the replicative capacity of affected cells.Type: GrantFiled: October 5, 2001Date of Patent: July 29, 2003Assignee: Geron CorporationInventors: Gregg B. Morin, Walter D. Funk, Mieczyslaw A. Piatyszek
-
Patent number: 6576464Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.Type: GrantFiled: February 13, 2001Date of Patent: June 10, 2003Assignee: Geron CorporationInventors: Joseph D. Gold, Jane S. Lebkowski